Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05532735 · ClinicalTrials.gov registry record · Phase 2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
A Phase 2 study of Retinal Vein Occlusion, sponsored by Annexin Pharmaceuticals AB.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 7
- Study locations
NCT05532735 is a Phase 2 study of Retinal Vein Occlusion that has completed, run by Annexin Pharmaceuticals AB. The registered enrollment target is 16 participants, below the 858-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05532735, a Phase 2 study of Retinal Vein Occlusion, has completed, sponsored by Annexin Pharmaceuticals AB.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 7
- Study locations
Study Summary
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
Conditions Studied
Interventions
- BIOLOGICAL ANXV
Study Locations (7)
Texas
- Retina Consultants of Texas - Bellaire
- Valley Retina Institute - McAllen
- Retina Consultants of Texas - San Antonio
Louisiana
- Eye Associates of Northeast Louisiana - West Monroe
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Oklahoma
- Tulsa Retina Consultants - Tulsa
Virginia
- Virginia Retina Center - Warrenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05532735
The ClinicalTrials.gov registry entry for NCT05532735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 858-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (98% lower). The listed sponsor is Annexin Pharmaceuticals AB, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which ANXV is the first listed.
NCT05532735 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Texas, Louisiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT05532735 about?
NCT05532735 is a clinical study titled "Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion". Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
What is the current status of trial NCT05532735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-08-24. Estimated completion is 2024-11-11.
What conditions does trial NCT05532735 study?
This clinical trial studies the following conditions: Retinal Vein Occlusion.
What interventions are being tested in trial NCT05532735?
The interventions under investigation include: ANXV (BIOLOGICAL).
Who is sponsoring clinical trial NCT05532735?
This trial is sponsored by Annexin Pharmaceuticals AB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05532735 being conducted?
This trial has 7 study locations across Louisiana, Maryland, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
COMPLETED · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
National Eye Institute Biorepository for Retinal Diseases
RECRUITING
-
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
RECRUITING · NA
-
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
ACTIVE NOT RECRUITING
-
30g vs 33g Needle for Intravitreal Injections
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.